# Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation

> **NCT03513328** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Florida** · enrollment: 6 (actual)

## Conditions studied

- Bone Marrow Failure Syndrome
- Thalassemia
- Sickle Cell Disease
- Diamond Blackfan Anemia
- Acquired Neutropenia in Newborn
- Acquired Anemia Hemolytic
- Acquired Thrombocytopenia
- Hemophagocytic Lymphohistiocytoses
- Wiskott-Aldrich Syndrome
- Chronic Granulomatous Disease
- Common Variable Immunodeficiency
- X-linked Lymphoproliferative Disease
- Severe Combined Immunodeficiency
- Hurler Syndrome
- Mannosidosis
- Adrenoleukodystrophy

## Interventions

- **DRUG:** Thiotepa--single daily dose
- **DRUG:** Thiotepa--escalated dose

## Key facts

- **NCT ID:** NCT03513328
- **Lead sponsor:** University of Florida
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-15
- **Primary completion:** 2022-02-17
- **Final completion:** 2023-02-19
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2023-09-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03513328

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03513328, "Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT03513328. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*